Heartbeam, INC 8-K filings

HeartBeam, Inc. has entered into an At-The-Market Equity Offering Sales Agreement with Titan Partners Securities LLC to sell up to $25 million of its common stock.

HeartBeam, Inc. is shifting to a licensing-led business model and reorganizing leadership following the departure of CEO Robert Eno.

HeartBeam, Inc. has successfully closed an underwritten public offering of 12,500,000 shares of common stock, raising $10 million in gross proceeds.

HeartBeam, Inc. received a Not Substantially Equivalent letter from the FDA for its 12-Lead ECG Synthesis Software, prompting the company to work towards a resolution while considering the launch of its 3D ECG system.

HeartBeam, Inc. announced the successful election of all nine director nominees, ratification of its independent auditor, and approval of an increase in authorized shares for its 2022 Equity Incentive Plan at its 2025 Annual Meeting.

HeartBeam, Inc. appoints CEO Robert Eno to its Board of Directors to support U.S. commercialization and growth.

HeartBeam, Inc. reports the resignation of Marcum LLP as their independent auditor and the engagement of CBIZ CPAs, effective April 21, 2025.

HeartBeam, Inc. announces the full exercise and closing of the underwriter's over-allotment option, resulting in total gross proceeds of $11.5 million from its public offering.

HeartBeam, Inc. announces the pricing of a $10 million public offering to support commercial readiness and R&D efforts.

HeartBeam, Inc. has appointed Robert Eno as its new CEO, while founder Branislav Vajdic transitions to the role of President, effective October 21, 2024.

HeartBeam, Inc. has appointed Timothy Cruickshank as its new Chief Financial Officer, effective September 9, 2024.

HeartBeam, Inc. successfully held its annual meeting, electing eight directors and approving an amendment to increase the number of shares available under its 2022 Equity Incentive Plan.

HeartBeam, Inc. has entered into a sales agreement with Public Ventures, LLC for a potential $17 million at-the-market offering of its common stock, while terminating a previous agreement with A.G.P./Alliance Global Partners.

HeartBeam's Chief Financial Officer, Richard Brounstein, retired effective February 1, 2024, after serving since 2015, and will transition into a consulting role.